ShangPharma Corporation (SHP)
ShangPharma Corporation Revenue Growth: 19.04%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SHP Revenue Growth Rankings
| Overall | 74th percentile | 1101 of 4363 |
| Sector | 69th percentile | 140 of 457 in Healthcare |
| Industry | 58th percentile | 52 of 126 in Biotechnology |
SHP Revenue Growth Range, Past 5 Years
| Minimum | 19.04% | Dec 2011 |
| Maximum | 29.36% | Dec 2010 |
| Average | 24.95% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these SHP related companies
SHP News
ShangPharma to Report First Quarter 2012 Financial Results on May 17, 2012
May 03, 8:00AM PR Newswire
May 03, 8:00AM PR Newswire
ShangPharma Corp. (SHP) Misses Q4 EPS by 4c; Issues Light FY12 Revs Outlook
Mar 12, 6:53AM Street Insider
Mar 12, 6:53AM Street Insider
ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012
Feb 28, 8:00AM PR Newswire
Feb 28, 8:00AM PR Newswire
ShangPharma (SHP) Receives First Milestone in Research Partnership with Hengrui
Jan 19, 8:04AM Street Insider
Jan 19, 8:04AM Street Insider
ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui
Jan 19, 8:01AM Benzinga
Jan 19, 8:01AM Benzinga
ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline
Jan 10, 8:00AM PR Newswire
Jan 10, 8:00AM PR Newswire
ShangPharma to Present at J.P. Morgan's 30th Annual Healthcare Conference
Dec 14, 8:00AM PR Newswire
Dec 14, 8:00AM PR Newswire
ShangPharma Corporation (SHP) Announces Resignation of Chief Operating Officer, Mr. Kevin Chen
Dec 12, 8:03AM Street Insider
Dec 12, 8:03AM Street Insider
ShangPharma to Report Third Quarter 2011 Financial Results on November 21, 2011
Nov 07, 8:00AM PR Newswire
Nov 07, 8:00AM PR Newswire
Just added a position with $SHP. Might not carry this overnight...will see what happens.
about 293 days ago by suPEARLative5
about 293 days ago by suPEARLative5
Market talk Astrazenca ($AZN LN) could be interested in Shire ($SHP LN) $$
about 408 days ago by RANsquawk
about 408 days ago by RANsquawk
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SHP | 6.43 | +0.05 | +0.78% | 119.11M |
| SHOR | 4.19 | +0.17 | +4.23% | 193.64M |
| SHOO | 40.48 | -0.09 | -0.22% | 1.785B |
| SHO | 10.00 | +0.20 | +1.99% | 1.168B |
| SHLO | 10.10 | +0.26 | +2.64% | 165.71M |
| SHLM | 21.36 | -0.32 | -1.48% | 637.61M |
| SHLD | 49.62 | -2.72 | -5.20% | 5.569B |
| SHIP | 2.29 | -0.02 | -0.87% | 27.39M |
| SHI | 28.65 | -0.35 | -1.21% | 884.50M |
| SCHW | 12.41 | -0.11 | -0.88% | 15.92B |
